Skip to main
CRMD
CRMD logo

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. has raised its full-year 2025 pro forma net revenue guidance to a range of $390–$410 million, reflecting stronger-than-expected adoption of its product DefenCath along with early contributions from the Melinta portfolio. The company projects fourth-quarter net revenue between $115 million and $135 million, indicating consistent momentum as they approach year-end and highlighting robust commercial execution. Furthermore, Cormedix's increased guidance for fully synergized pro forma adjusted EBITDA to $220–$240 million underscores its solid financial performance and improving operational metrics.

Bears say

Cormedix Inc faces significant pricing pressure as DefenCath's price is expected to drop substantially with the second phase of the TDAPA reevaluation set for July 2026. The uncertainty surrounding TDAPA pricing could hinder sales projections of DefenCath, especially in a competitive landscape that includes lower-cost generic alternatives like Heparin. Additionally, while there are suggested growth opportunities within the Niyadas product range, the overall dependence on a single product within a narrow market confines presents substantial risk to the company's financial stability and long-term outlook.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.